In addition, given the possible sub-optimality of the IHC/ISH-based method in the detection of HER2-low breast cancer patients, alternative technologies for a quantitative evaluation of HER2 have been suggested as potentially capable of improving our ability to identify this emerging breast cancer subset34–39, however none of them have yet been formally validated. The gene discussed is ERBB2; the disease is breast carcinoma.